WVE SCHEDULE 13G/A: SEC filing
Maverick Capital
Filed with the SEC on · accession 0001012975-26-001060
WVE filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. A report the company filed with the SEC (the US market regulator).
Summary of the filing
Maverick Capital filed an amended Schedule 13G indicating it no longer beneficially owns any shares of Wave Life Sciences, reducing its position to 0% as of September 30, 2026.
Key details
✦ Ask GOAX AI about this filing — what it means for WVE, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for WVE?
Click hereFrequently asked questions
What did WVE file with the SEC on Nov 16, 2026?
WVE filed a SCHEDULE 13G/A (SEC filing). Maverick Capital filed an amended Schedule 13G indicating it no longer beneficially owns any shares of Wave Life Sciences, reducing its position to 0% as of September 30, 2026.
How do I read a SCHEDULE 13G/A?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).
Other WVE SEC filings
- SCHEDULE 13G · SEC filingOct 27, 2026
- SCHEDULE 13G/A · SEC filingOct 27, 2026
- 8-K · SEC filingOct 27, 2026
- 10-Q · SEC filingOct 27, 2026
- DEF 14A · Board changeOct 14, 2026
- SCHEDULE 13D/A · SEC filingAug 11, 2026
- 8-K · SEC filingJul 30, 2026
- 10-Q · SEC filingJul 30, 2026
- 8-K · SEC filingJun 26, 2026
- 8-K · Fda approvalMay 18, 2026
Get alerts when WVE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days